|
|
|
| Effect of Shenqi Yiliu Formula combined with radiotherapy on immune function and prognosis of patients with middle and advanced cervical cancer |
| HUANG Chunlan1 HONG Huiqin2 SUN Yingfang3 ZENG Junlin4 YUAN Li1 ZOU Chengxiu1 LI Meili1 |
1. Department of Radiotherapy, Ganzhou Cancer Hospital, Jiangxi Province, Ganzhou 341000, China;
2. Department of Emergency, the First Affiliated Hospital of Gannan Medical College, Jiangxi Province, Ganzhou 341000, China;
3. Department of Nursing, Hospital of Gannan Normal University, Jiangxi Province, Ganzhou 341000, China;
4. Fuzhou Medical College, Nanchang University, Jiangxi Province, Fuzhou 344000, China |
|
|
|
|
Abstract Objective To explore the effect of Shenqi Yiliu Formula combined with radiotherapy on immune function and prognosis of patients with middle and advanced cervical cancer. Methods A total of 84 patients with advanced cervical cancer treated in Ganzhou Cancer Hospital from April 2015 to October 2018 were selected as the research subjects. According to random number table method, they were divided into control group (42 cases) and observation group (42 cases). The control group was treated with radiotherapy, and the observation group was treated with Shenqi Yiliu Formula combined with radiotherapy. The disease control rate, objective remission rate, immune function and prognosis were compared between the two groups. Results The objective remission rate of the observation group was 71.43%, higher than 47.62% of the control group, and the disease control rate of the observation group was 90.48%, higher than 69.05% of the control group, the differences were statistically significant (P<0.05). After treatment, CD3+, CD4+ and natural killer (NK) cells in the observation group were higher than those in the control group, the differences were statistically significant (P<0.05). The 3-year survival rate of the observation group was higher than that of the control group, and the overall incidence of tumor metastasis was lower than that of the control group, the differences were statistically significant (P<0.05). Conclusion Shenqi Yiliu Formula combined with radiotherapy has reliable efficacy in the treatment of patients with middle and advanced cervical cancer, which can improve immune function, reduce the total incidence of tumor metastasis and improve the 3-year survival rate.
|
|
|
|
|
|
| [1] |
Liu C，Xiao C，Chen J，et al.Risk factor analysis for predicting cervical lymph node metastasis in papillary thyroid carcinoma：a study of 966 patients[J]. BMC Cancer，2019，19（1）：622.
|
| [2] |
郑彩红，唐之雅，刘挺.奈达铂、紫杉醇联合同期放疗治疗中晚期宫颈癌的可行性研究[J].中国医药科学，2020，10（6）：245-247，283.
|
| [3] |
曾春生，余瑛，徐青云，等.金龙胶囊在宫颈癌术后调强放疗复发转移中的应用效果[J].中国当代医药，2021，28（28）：148-151.
|
| [4] |
曲波，王海琳，吴红彦，等.参芪抑瘤方联合新辅助化疗治疗中晚期宫颈癌临床疗效分析[J].西部中医药，2017，30（8）：1-4.
|
| [5] |
中国抗癌协会妇科肿瘤专业委员会.宫颈癌诊断与治疗指南（第四版）[J].中国实用妇科与产科杂志，2018，34（6）：613-622.
|
| [6] |
Tsikouras P，Zervoudis S，Manav B，et al.Cervical cancer： screening，diagnosis and staging[J].J BUON，2016，21（2）：320-325.
|
| [7] |
杨学宁，吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学，2004，4（2）：85-90，111.
|
| [8] |
李道娟，师金，靳晶，等.宫颈癌的流行病学趋势[J].中华肿瘤杂志，2021，43（9）：912-916.
|
| [9] |
赵雪，姜静，张川利，等.术前新辅助化疗联合手术治疗宫颈癌患者临床疗效及术后生存预测因素分析[J].实用医院临床杂志，2021，18（3）：153-157.
|
| [10] |
罗然，李贤富，陈俊安，等.放疗对宫颈癌患者性生活质量的影响及处理研究进展[J].癌症进展，2021，19（16）：1628-1630，1727.
|
| [11] |
陈顺泰，花宝金.中医药防治宫颈癌人乳头瘤病毒感染的研究进展[J].吉林中医药，2020，40（2）：275-277.
|
| [12] |
郝志晔，张晶，钱伟，等.参芪排毒汤对宫颈癌组织人乳头瘤病毒E6/E7、P53和PRb基因蛋白表达的影响[J].陕西中医，2021，42（2）：192-195，199.
|
| [13] |
黄春兰，刘华之.参芪抑瘤方联合新辅助化疗对中晚期宫颈癌患者免疫功能及预后的影响[J].当代医学，2021， 27（17）：139-140.
|
| [14] |
朱凯敏，马春林，李红亮，等.参芪抑瘤方联合顺铂对MFC荷瘤小鼠瘤组织XIAP、PTEN表达的影响[J].辽宁中医杂志，2019，46（2）：418-421，后插6.
|
| [15] |
王帅.康莱特注射液联合化疗对老年宫颈癌患者血清肿瘤标志物、T淋巴细胞亚群、炎症因子及生活质量的影响[J].中国老年学杂志，2021，41（14）：2962-2965.
|
| [16] |
谭细凤，徐慧君，郭丽华，等.宫颈癌术后感染患者T淋巴细胞免疫功能变化及其临床意义[J].中华医院感染学杂志，2015，25（6）：1270-1272.
|
| [17] |
胡妮娜，张晓娟.黄芪的化学成分及药理作用研究进展[J].中医药信息，2021，38（1）：76-82.
|
| [18] |
苏佳昇，李晓霞，蒋雅娴，等.苦参化学成分与药理作用研究进展[J].湖北农业科学，2021，60（1）：5-9.
|
|
|
|
